US biotech Lyell Immunopharma (Nasdaq: LYEL) has broadened its cell therapy portfolio by acquiring global rights to LYL273, a guanylyl cyclase-C (GCC)-targeted CAR T candidate from Innovative Cellular Therapeutics.
The therapy, designed for metastatic colorectal cancer and other GCC-expressing tumors, showed a 67% overall response rate and an 83% disease control rate at the highest dose tested in a Phase I US trial.
The candidate, previously known as GCC19CART, uses controlled cytokine release and CD19 CAR expression to enhance immune cell infiltration and tumor killing in the solid tumor microenvironment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.